NCT01841021 2017-01-19
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
H. Lee Moffitt Cancer Center and Research Institute
Yale University